Chestnut Shell Extract Composition for Low-Toxicity Antiviral Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for viral infections caused by Herpesviridae, Retroviridae, and Coronaviridae families face challenges such as drug resistance, inability to eradicate latent infections, and the need for effective, low-toxicity alternatives to synthetic drugs, particularly for HSV-1, HSV-2, HIV, and SARS-CoV-2.
Innovation Solution
Utilizing a natural extract from chestnut shells (CSE) obtained through traditional or non-traditional methods, demonstrating high efficacy in inhibiting HSV-1, HSV-2, HIV, and SARS-CoV-2 replication and growth, with minimal toxicity even at high concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If synthetic antiviral drugs are used to treat viral infections, then viral replication is inhibited, but drug resistance develops and latent infections cannot be eradicated
Solution Approach 1:
The patent changes the chemical parameter from synthetic drugs to natural polyphenolic compounds extracted from chestnut shells. This parameter change results in antiviral activity against HSV-1, HSV-2, HIV, and SARS-CoV-2 without inducing drug resistance or failing to eradicate latent infections, as demonstrated by the natural extract's ability to inhibit viral replication across multiple virus families without the resistance problems associated with conventional synthetic antivirals
Solution Approach 2:
The patent utilizes chestnut shells, an agricultural waste product, as the source of antiviral compounds. This approach replaces expensive synthetic drug production with a low-cost, renewable natural resource. The chestnut shells are extracted for their polyphenolic content and the extract can be used effectively without requiring long-term accumulation or complex synthesis procedures
2Object-affected harmful factors
If natural extracts from chestnut shells are used, then viral replication is inhibited with low toxicity, but the extract concentration must be optimized to achieve efficacy
Solution Approach 1:
The patent demonstrates that the chestnut shell extract exhibits antiviral activity at very low concentrations (2-20 µg/mL), which is considered partial action compared to the high concentrations sometimes required by other natural extracts. This partial action is sufficient to inhibit viral replication effectively while maintaining low toxicity, even though the exact optimal concentration varies by virus type and requires some optimization
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 1E~1G
AI summary
The present invention refers to the use of an extract from chestnut shells (CSE), peeling waste of the chestnut, (fruit of the tree Castanea sativa Mill., European Chestnut), or fractions of said extract, with specific antiviral activity in the treatment and/or prevention of Herpesviridae, Retroviridae, and Coronaviridae infections.